ResultsIQ › Latest results › 3B Blackbio Dx Limited
3B Blackbio Dx Limited Q2 FY27 results deck summary
NSE: 3BBLACKBIO · BSE: 532067
Results deck of 13 Nov 2026, summarised by AI from the filing.
3B BlackBio's H1 FY27 consolidated revenue from operations was ₹8,177.10 lakh, with MDx growth hoped at 15%–20% for FY 2026–27.
Key takeaways
- H1 revenue Consolidated revenue from operations ₹8,177.10 lakh (H1 2025-26: ₹5,613.67 lakh), including Coris sales of ₹1,780.23 lakh and a Coris EBITDA loss of ₹331 lakh.
- MDx guidance Management hopes MDx grows 15%–20% overall in FY 2026–27 across domestic and export sales, with geo-political tensions affecting sales as of now.
- Coris consolidation This is the first year with full H1 Coris numbers consolidated, versus consolidation only from 29 August 2025 last year.
- Export growth Exports rose to ₹657.49 lakh in Q2 FY27 from ₹497.85 lakh in Q2 FY26, with presence in 70+ countries and 200+ customers.
- Geopolitical risk Geo-political tensions are affecting sales, with some orders delayed or cancelled and logistics challenging.
3B Blackbio Dx Limited earnings call, investor presentation and press release summaries
- Q2 FY27: Results deck (13 Nov 2026)
- Q1 FY27: Results deck (13 Aug 2026)
- Q4 FY26: Earnings call (1 Jun 2026), Results deck (29 May 2026)
- Q3 FY26: Earnings call (21 Feb 2026), Results deck (6 Feb 2026)
- Q2 FY26: Results deck (13 Nov 2025)
- Q1 FY26: Earnings call (19 Aug 2025)
- Q4 FY25: Results deck (28 May 2025)
- Other events: Strategy deck (14 Aug 2025)
Figures from the company's filings with NSE and BSE. Not investment advice.